Giulio Diamante, MD
Ophthalmology · Johnston, RINPI 1851379812
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,434 of the $6,080 with a category attached, or 72.9%. 25 manufacturers reported payments, led by Aesculap, Inc. at 27.1% of the total. Reporting peaked in 2024 at $2,319 and has fallen 53.6% since, to $1,077 in 2025. Among ophthalmology clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $34.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aesculap, Inc.$2K
- Alcon$955
- AbbVie$779
- Glaukos Corporation$431
- Rxsight Inc$370
- Bausch & Lomb Americas Inc.$226
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,43473%
- Other$1,64627%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aesculap, Inc. | 1 | $1,646 |
| Alcon | 56 | $955 |
| AbbVie(2 entities) | 37 | $779 |
| Glaukos Corporation | 4 | $431 |
| Rxsight Inc | 3 | $370 |
| Bausch & Lomb Americas Inc. | 11 | $226 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $224 |
| Kala Pharmaceuticals, Inc. | 11 | $182 |
| NEW World Medical,inc. | 3 | $154 |
| Tarsus Pharmaceuticals, Inc. | 2 | $148 |
| Sun Pharmaceutical Industries Inc. | 7 | $138 |
| Novartis | 7 | $130 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $118 |
| Oyster Point Pharma, Inc. | 4 | $103 |
| Amgen(2 entities) | 5 | $87 |
| Aerie Pharmaceuticals, Inc. | 4 | $69 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 2 | $61 |
| Carl Zeiss Meditec, Inc. | 1 | $58 |
| Biotissue Holdings Inc. | 2 | $41 |
| Rayner Intraocular Lenses Limited | 2 | $36 |
| Dompe US, Inc. | 1 | $33 |
| Eyevance Pharmaceuticals LLC | 2 | $27 |
| LKC Technologies, Inc. | 1 | $25 |
| Thea Pharma Inc. | 1 | $22 |
| Omeros Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iDoseTR$372
- RXSIGHT CONTACT LENS$351
- RXSIGHT INJECTOR CARTRIDGE$351
- RXSIGHT INJECTOR HANDPIECE$351
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$351
- DURYSTA$248
- LIGHT ADJUSTABLE LENS (LAL)$219
- Tecnis IOL$192
- Whitestar Signature$192
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$132
- Kahook Dual Blade$127
- Clearpath$127
- Ahmed Glaucoma Valve$127
- Streamline$127
- Via360$127
- XDEMVY$123
- VUITY$102
How this compares
$6,080 in reported general payments places this provider in the 90th percentile of 69 ophthalmology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 150 | $58,000 |
| Bromfenac Sodium | 180 | $41,197 |
| Prednisolone Acetate | 841 | $29,330 |
| ProlensaBromfenac Sodium | 79 | $27,147 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 62 | $21,939 |
| RocklatanNetarsudil Mesylat/Latanoprost | 57 | $18,572 |
| CombiganBrimonidine Tartrate/Timolol | 62 | $17,720 |
| Latanoprost | 868 | $13,353 |
| RestasisCyclosporine | 13 | $12,613 |
| VyzultaLatanoprostene Bunod | 18 | $9,395 |
| Ofloxacin | 574 | $8,252 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 365 | $8,128 |
| Timolol Maleate | 227 | $6,969 |
| RhopressaNetarsudil Mesylate | 11 | $6,967 |
| AzoptBrinzolamide | 19 | $6,917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis | $779 | $88,334225 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance | $118 | $29,93492 claims |
| AlconSimbrinza, Azopt | $955 | $28,85681 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $69 | $25,53968 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $226 | $9,39518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 69 ophthalmology providers in Rhode Island.
Other ophthalmology in Johnston
- Nikolas RaufiJohnston$5K
- William AndreoniJohnston$2K
- Sarah AnisProvidence$163K
- Sarah LevyWakefield$148K
- Nermin GraiseWarwick$60K
- Jesse RichmanProvidence$30K
- Alex GerberMiddletown$15K
- Yoash EnzerProvidence$11K
- David TienProvidence$6K
- Leah KammerdienerWarwick$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.